BCAX
Bicara Therapeutics Inc. Common Stock · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -7.1% ·
share flow +2.2% ·
net new positions -15.4%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 71 | +6 | 22.19M | $658.02M | +11 | −5 |
| Q1 2026 | 68 | +4 | 22.46M | $446.36M | +8 | −5 |
| Q4 2025 | 65 | 0 | 22.60M | $380.21M | +3 | −2 |
| Q3 2025 | 13 | -1 | 12.02M | $189.85M | — | −2 |
| Q2 2025 | 12 | 0 | 11.43M | $106.16M | +3 | −3 |
| Q1 2025 | 9 | +1 | 5.34M | $69.55M | +2 | −1 |
| Q4 2024 | 8 | -3 | 5.77M | $100.60M | +1 | −4 |
| Q3 2024 | 10 | +10 | 4.16M | $105.86M | +10 | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 2.70M | +6.3% | $42.61M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (passive) | 2.31M | +9.5% | $36.50M | 0.0% | ▲ Add | 2 | SEC ↗ ×8 |
| 3 | The Vanguard Group ✦ (passive) | 2.20M | +9.8% | $34.75M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 4 | T. Rowe Price ✦ | 1.76M | -18.4% | $27.72M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 5 | Millennium Management ✦ | 1.01M | +37.0% | $16.03M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 831.21K | +23.6% | $13.13M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 7 | State Street Global Advisors ✦ (passive) | 590.28K | +9.1% | $9.32M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Goldman Sachs Group ✦ | 232.76K | — | $3.68M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | Marshall Wace ✦ | 112.09K | +116.3% | $1.77M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 10 | Morgan Stanley ✦ | 100.03K | — | $1.58M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 11 | Two Sigma Investments ✦ | 95.24K | -29.2% | $1.50M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | JPMorgan Chase ✦ | 49.87K | — | $787,446 | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 13 | Point72 Asset Management ✦ | 30.14K | -86.1% | $475,885 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Citadel Advisors | $2.06M | was 0.0% |
| Norges Bank | $398,439 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 146 holders, 71.07M shares, $1.23B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 14.06K sh · $320,053
Officer, Director · 3.44K sh · $80,663
Officer, Director · 10.00K sh · $279,750
Officer · 12.50K sh · $349,591
Officer, Director · 18.75K sh · $524,533
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology